Allarity Therapeutics : Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) - Form 8-K

Allarity Therapeutics Receives Nasdaq Notification
of Non-Compliance with Listing Rule 5250


Cambridge, MA U.S.A. - Allarity Therapeutics, Inc. , a clinical-stage... | April 22, 2022

Related Keywords

United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Denmark ,Thomas Pedersen ,Chuck Padala ,Jens Knudsen ,Linkedin ,Twitter ,Company Contact ,Carrotize Pr Communications ,Nasdaq Hearings Panel ,Nasdaq ,Exchange Commission ,Allarity Therapeutics Inc ,Smerud Medical Research International ,Facebook ,Allarity Therapeutics Receives Nasdaq ,Listing Rule ,Listing Qualifications Department ,Nasdaq Stock Market ,Nasdaq Listing Rule ,Annual Report ,Nasdaq Listing ,Nasdaq Hearings ,Chosa Aps ,Drug Response Predictor ,Private Securities Litigation Reform Act ,Allarity Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Allarity ,Herapeutics ,Eceives ,F ,Ith ,Listing ,Mule ,A ,Llarity Allr Us0167441049 ,